Cancer Therapeutics Program, Ottawa Hospital Research Institute, Ottawa, Canada.
Department of Medicine, University of Ottawa, Ottawa, Ontario, Canada.
Cancer Gene Ther. 2022 Feb;29(2):156-166. doi: 10.1038/s41417-021-00320-w. Epub 2021 Mar 22.
In spite of significant recent advances in our understanding of the genetics and cell biology of glioblastoma, to date, this has not led to improved treatments for this cancer. In addition to small molecule, antibody, and engineered virus approaches, engineered cells are also being explored as glioblastoma therapeutics. This includes CAR-T cells, CAR-NK cells, as well as engineered neural stem cells and mesenchymal stem cells. Here we review the state of this field, starting with clinical trial studies. These have established the feasibility and safety of engineered cell therapies for glioblastoma and show some evidence for activity. Next, we review the preclinical literature and compare the strengths and weaknesses of various starting cell types for engineered cell therapies. Finally, we discuss future directions for this nascent but promising modality for glioblastoma therapy.
尽管我们在胶质母细胞瘤的遗传学和细胞生物学理解方面取得了重大的最新进展，但迄今为止，这并没有导致这种癌症的治疗方法得到改善。除了小分子、抗体和工程病毒方法外，工程细胞也被探索作为胶质母细胞瘤的治疗方法。这包括 CAR-T 细胞、CAR-NK 细胞，以及工程化的神经干细胞和间充质干细胞。在这里，我们从临床试验研究开始，综述了这一领域的现状。这些研究已经证实了工程细胞疗法治疗胶质母细胞瘤的可行性和安全性，并显示出一些活性证据。接下来，我们回顾了临床前文献，并比较了各种起始细胞类型用于工程细胞疗法的优缺点。最后，我们讨论了这种用于胶质母细胞瘤治疗的新兴但有前途的模式的未来方向。
